Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zentalis Pharmaceuticals Inc (NQ: ZNTL )

5.250 +1.110 (+26.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,060,691
Open 4.310
Bid (Size) 5.260 (3)
Ask (Size) 5.340 (47)
Prev. Close 4.140
Today's Range 4.100 - 5.700
52wk Range 3.930 - 30.53
Shares Outstanding 45,052,904
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga

Performance

YTD
-67.17%
-67.17%
1 Month
-54.66%
-54.66%
3 Month
-61.71%
-61.71%
6 Month
-63.29%
-63.29%
1 Year
-82.30%
-82.30%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Analyst Expectations for Zentalis Pharma's Future
Via Benzinga
Where Zentalis Pharma Stands With Analysts
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Is Small-Cap Cancer-Focused Zentalis Pharma Stock Trading Lower On Tuesday?
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
ZNTL Stock Earnings: Zentalis Pharma Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Analyst Expectations for Zentalis Pharma's Future
Via Benzinga
Zentalis Gears Up for Phase 3 Study of Azenosertib after Positive Phase 1b Outcomes
Via Benzinga
Where Zentalis Pharma Stands With Analysts
Via Benzinga
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
Via Talk Markets
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
From Immunome, Inc.
Via Business Wire
Morgan Stanley Maintains Overweight Rating for Zentalis Pharma: Here's What You Need To Know
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Zentalis Pharma: Q1 Earnings Insights
Via Benzinga
TreeHouse Foods, EchoStar, Hilton Grand Vacations, EchoStar And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Around $108M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
5 Short Squeeze Stocks In Play Thursday: Nikola, Verve, Carvana, More
Via Benzinga
Domino's Pizza, Patterson-UTI Energy, JinkoSolar And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Why Shares of Zentalis Pharmaceuticals Dropped This Week
Via The Motley Fool
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.